Humanigen Aligns with FDA on Potential Registration Phase 3 Study for Lenzilumab with CAR-T

FDA Type C meeting and advice creates alignment on registration pathway for Phase 3 clinical development of lenzilumab for the prevention of CAR-T therapy related toxicities including Immune Effector Cell-Associated Neurotoxicity (ICANS) and Cytokine